GRML Greenland Mines Ltd
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1907223 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-199.9%
TTM EPS YoY109.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-44.3%
ROA-44.0%
ROIC (approx.)-56.3%
Asset turnover—
Leverage & solvency
Liabilities / assets1.0%
Debt / equity0.00x
Current ratio62.16x
Interest coverage25.06x
Cash quality & payout
Operating cash flow / net income0.72x
Accruals ratio-12.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | — | — | — |
| R&D expense | $634,187 | $0 | $0 | — |
| SG&A expense | $3.08M | $2.78M | $30,546 | $533,992 |
| Operating income | -$7.15M | -$5.54M | -$631,322 | -$657,018 |
| Interest expense | $2.31M | $356,603 | $76,214 | — |
| Pretax income | -$10.55M | -$6.15M | -$707,458 | $1.56M |
| Income tax | — | — | $690,572 | $322,025 |
| Net income | -$10.55M | -$6.15M | -$707,458 | $1.23M |
| EPS (basic) | -0.22 | -0.32 | -0.05 | — |
| EPS (diluted) | -0.22 | -0.32 | -0.05 | — |
| Dividends declared per share | — | — | 16.50 | 16.50 |
| Weighted avg. shares (diluted) | 48.49M | 19.25M | 15.13M | — |
| Banking | ||||
| Deposits | — | — | $35,000 | — |
| Balance sheet | ||||
| Cash & equivalents | $7.18M | $63,741 | $2,808 | $75,872 |
| Current assets | $7.29M | $157,811 | $6,648 | $440,158 |
| PP&E, net | $0 | — | — | — |
| Intangibles | $2.30M | — | $2.19M | — |
| Total assets | $9.59M | $2.46M | $2.19M | $118.25M |
| Current liabilities | $76,764 | $1.25M | $1.62M | $506,241 |
| Total liabilities | $129,764 | $1.27M | $1.62M | $4.93M |
| Shareholders' equity | $9.46M | $1.19M | -$442,701 | -$4.04M |
| Shares outstanding | 1.48M | 27.08M | 15.13M | 3.40M |
| Cash flow statement | ||||
| Operating cash flow | -$5.89M | -$2.95M | -$446,916 | -$493,043 |
| Investing cash flow | — | -$123,497 | $23,852 | -$116.15M |
| Financing cash flow | $13.00M | $3.13M | $350,000 | $116.98M |
| Stock-based compensation | $1.57M | $2.65M | $0 | — |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.